头孢他啶阿维巴坦钠致中性粒细胞及血小板增多一例

Neutrophilic leukocytosis and thrombocytosis caused by ceftazidime and avibactam sodium:a case report

本文报道1例48岁男性肾移植术后患者因耐碳青霉烯肺炎克雷伯菌感染使用头孢他啶阿维巴坦钠治疗导致中性粒细胞、血小板异常增多的案例。患者使用头孢他啶阿维巴坦钠治疗20 d后出现中性粒细胞、血小板持续异常增多,经临床药师会诊建议停用头孢他啶阿维巴坦钠后,患者中性粒细胞、血小板逐渐降低并恢复。因此,长疗程使用头孢他啶阿维巴坦钠治疗应警惕中性粒细胞及血小板异常增多的不良反应,临床药师在其药学监护过程中发挥重要作用。

The article reported a case of a 48-year-old male patient who was treated with ceftazidime and avibactam sodium due to carbapenem-resistant klebsiella pneumoniae infection after renal transplantation,resulting in neutrophilic leukocytosis and thrombocytosis.After 20 days of ceftazidime avibactam sodium treatment,the patient developed a persistent abnormal increase in neutrophils and platelets.After consultation with a clinical pharmacist,the physicians were advised to discontinue the ceftazidime avibactam sodium,and then the neutrophils and platelets gradually decreased and recovered.Therefore,patients should be alert to the adverse reactions of neutrophilic leukocytosis and thrombocytosis when using ceftazidime avibactam sodium for long-term treatment,and clinical pharmacists can play an important role in pharmaceutical care.